Maxim Group analyst Caroline Palomeque reiterated a Buy rating and $3.00 price target on Agile Therapeutics (NASDAQ: AGRX) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE